3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Dermatologic
1
Conditions
Lymphoma, Non-Hodgkin
3
Hodgkin Disease
3
Sarcoma
2
Neoplasm Metastasis
2
Multiple Myeloma
2
Lymphoma, Mantle-Cell
2
Lymphoma, Large B-Cell, Diffuse
2
Lymphoma
2
Leukemia, Lymphocytic, Chronic, B-Cell
2
Ureteral Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Neoplasms by Site
1
Melanoma
1
Lymphoma, T-Cell, Peripheral
1
Lymphoma, T-Cell, Cutaneous
1
Lymphoma, Follicular
1
Lymphoma, B-Cell, Marginal Zone
1
Lung Neoplasms
1
Leukemia
1
Disease Progression
1
Carcinoma, Transitional Cell
1
Carcinoma, Non-Small-Cell Lung
1
Bronchiolitis Obliterans Syndrome
1
Interventions
Cyclophosphamide
19
romidepsin
15
fludarabine phosphate
13
Whole-Body Irradiation
13
Peripheral Blood Stem Cell Transplantation
11
Mycophenolic Acid
11
Doxorubicin
11
Vincristine
10
Prednisone
10
Cyclosporine
10
10-propargyl-10-deazaaminopterin
10
Gemcitabine
8
Etoposide
8
Alemtuzumab
8
Bortezomib
6
Dexamethasone
5
Busulfan
5
Brentuximab Vedotin
5
mogamulizumab
4
denileukin diftitox
4
darinaparsin
4
Vitamin B 12
4
Nivolumab
4
Lenalidomide
4
Folic Acid
4
Carboplatin
4
carfilzomib
3
belinostat
3
Tacrolimus
3
Rituximab
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Lymphoma, T-Cell, Peripheral
×
abexinostat
×
Clear all
NCT00724984
2014-04-07
PCYC-0403
Pharmacyclics LLC.
Phase 1/2
Completed
55 enrolled
11 charts